Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

1.990 +0.610 (+44.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptevo Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Aptevo Therapeutics: Q2 Earnings Insights
  Aptevo Therapeutics (NASDAQ:APVO) reported its Q2 earnings results on Thursday, August 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to Date 
From Aptevo Therapeutics
Via AccessWire
Recap: Aptevo Therapeutics Q1 Earnings
Aptevo Therapeutics (NASDAQ:APVO) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Are Aptevo Therapeutics Shares Trading Higher Today?
Aptevo Therapeutics Inc (NASDAQ: APVO)  
Via Benzinga
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto. 
Via Benzinga
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology... 
From Aptevo Therapeutics
Via AccessWire
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant Disease SEATTLE, WA / ACCESSWIRE / April 12, 2022 / Aptevo... 
From Aptevo Therapeutics
Via AccessWire
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia
Patients in Both Monotherapy and Combination Arms in Multi-Cohort Trial Have Achieved Transplant Eligible Status SEATTLE, WA / ACCESSWIRE / March 29, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a... 
From Aptevo Therapeutics
Via AccessWire
Aptevo Therapeutics Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q4, Aptevo Therapeutics (NASDAQ:APVO) posted sales of $3.67 million. Earnings were up 10.36%, but Aptevo Therapeutics still reported an... 
Via Benzinga
63 Biggest Movers From Yesterday
Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire. Global Internet... 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Rises 150 Points; Emclaire Financial Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Nasdaq composite gaining over 150 points on Thursday. The Dow traded up 0.76% to 34,621.33 while the NASDAQ rose 1.19... 
Via Benzinga
Why Did Aptevo Therapeutics Stock Jump 25% Today?
Aptevo Therapeutics Inc (NASDAQ: APVO) shares are trading higher Thursday after the company reported 2021 financial results. Aptevo said royalty revenue totaled $... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV) stock increased by 26.3% to $1.73 during Thursday's regular session. The current volume of 55.2 million shares is 5751.8... 
Via Benzinga
Mid-Day Market Update: Dow Surges 250 Points; LiqTech International Shares Slide
U.S. stocks traded higher midway through trading, with the Dow Jones jumping 250 points on Thursday. The Dow traded up 0.75% to 34,617.38 while the NASDAQ rose 1.08% to 14,072.31... 
Via Benzinga
34 Stocks Moving In Thursday's Mid-Day Session
Gainers JX Luxventure Limited (NASDAQ: LLL) shares jumped 37.7% to $4.64. Emclaire Financial Corp (NASDAQ: EMCF) shares climbed 32.8% to $38.35 after the company and... 
Via Benzinga
Aptevo Therapeutics: Q4 Earnings Insights
Aptevo Therapeutics (NASDAQ:APVO) reported its Q4 earnings results on Thursday, March 24, 2022 at 08:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update
SEATTLE, WA / ACCESSWIRE / March 24, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its... 
From Aptevo Therapeutics
Via AccessWire
60 Biggest Movers From Yesterday
Gainers US Ecology, Inc. (NASDAQ: ECOL) shares surged 67.7% to close at $47.25 on Wednesday after Republic Services reported it will buy the company at $48 per share in cash.... 
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers US Ecology, Inc. (NASDAQ: ECOL) shares jumped 68.1% to $47.34 after Republic Services reported it will buy the company at $48 per share in cash. Tritium DCFC Limited (... 
Via Benzinga
Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update
APVO436 Phase 1b Trial for Acute Myeloid Leukemia Adds New Site Complete Remission Patient to Advance to Transplant SEATTLE, WA / ACCESSWIRE / February 9, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or... 
From Aptevo Therapeutics
Via AccessWire
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Aptorum Group (NASDAQ:APM) stock m... 
Via Benzinga
Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022
Vice Chairman, John E. Niederhuber, M.D., to Assume Chairmanship, Effective April 1, 2022 SEATTLE, WA / ACCESSWIRE / January 21, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company")... 
From Aptevo Therapeutics
Via AccessWire
Topics Retirement
Exposures Pension
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"
LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / December 15, 2021 / Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced publication of an article in the... 
From Aptevo Therapeutics
Via AccessWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, investor! With our return from the weekend comes a dive into the biggest pre-market stock movers for Monday! 
Via InvestorPlace
22 Stocks Moving in Monday's Pre-Market Session
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 32.6% to $3.58 in pre-market trading after gaining more than 14% on Friday. Foghorn Therapeutics Inc. (NASDAQ: FHTX) rose... 
Via Benzinga
61 Biggest Movers From Yesterday
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) shares jumped 44.1% to close $4.61 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) climbed 91.7% to $6.14 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down Moderna's... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.